NCT04432454
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: ESR1
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Endocrine (Hormone) Therapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with more than 2 endocrine treatment regimens for metastatic disease- see trial for details; Patients with more than one cytotoxic chemotherapy regimen for metastatic disease; Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04432454